Phase 3 REGAL Win: Cancer Vaccine Cuts Death Risk 41% in AML, Median Survival 24.0 vs 14.7 Months
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS's pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary overall survival endpoint in second-remission AML patients ineligible for transplant. GPS cut the risk of death by 41% (hazard ratio 0.59, p=0.035), with median OS of 24.0 months versus 14.7 months on best available treatment. Safety was consistent with prior experience and no new signals emerged. This is the binary event the stock has been waiting on: the company hit the pre-specified 80th death event on October 28, and today's readout delivers a positive result rather than just the trigger. SELLAS now plans to meet the FDA on an accelerated filing strategy and prepare a BLA submission in the first half of 2027. The company ended Q3 with $134.7 million in cash, enough for at least twelve months, so funding the BLA path is not an immediate constraint. Watch the 7:45 a.m. ET webcast today and the FDA interaction timing for the filing path.
At the time of this announcement, SLS was trading at $8.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.39 to $15.88. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: GlobeNewswire.